Table 1.  Grading skin toxicities associated with EGFR inhibitors according to NCI-CTC AE version 4.0.

Adverse event	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Rash acneiform	Papules and/or pustules covering <10% BSA which may or may not be associated with symptoms of pruritus or tenderness	Papules and/or pustules covering 10 - 30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL	Papules and/or pustules covering >30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; limiting self care ADL; associated with local superinfection with oral antibiotics indicated	Papules and/or pustules covering any % BSA, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated; lifethreatening consequences	death
Skin pain	Mild pain	Moderate pain; limiting instrumental ADLs	Severe pain; limiting self-care ADLs	–	–
Skin and subcutaneous tissue disorders, and others specifically paronychia and skin fissures	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated	Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADLs	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; disabling; limiting self care ADLs	Life-threatening consequences; urgent intervention indicated	Death

BSA, body surface area.